Benefits (Research Focus) FOXO4-p53 PPI research studied as a selective disruptor of the FOXO4p53 protein-protein interaction in cellular research models p53 transactivation domain pharmacology investigated for targeting the p53 transactivation domain surface in PPI inhibitor research Cellular senescence research explored for senescence-associated apoptosis pathway endpoints in cell culture research models D-retro-inverso peptide chemistry examined for peptidase resistance and SAR studies of D-amino-acid sequence-reversed peptide design SASP marker research researched for senescence-associated secretory phenotype marker dynamics (p16, IL-6) in cell research What Researchers Look At FOXO4-p53 binding interface analysis and competitive PPI disruption assays p16 INK4a , IL-6, and other SASP marker expression in senescent cell research models Apoptosis induction (caspase activation, Annexin V staining) in senescent versus non-senescent cell research D-retro-inverso versus L-peptide comparative stability and biological activity research Comparative pharmacology versus other senolytic research compounds and PPI inhibitors Quick Specs Form: Lyophilized white powder Net Peptide Content: 10 mg per vial Quantity: 1 vial Appearance: White to off-white lyophilizate Reconstitution: Bacteriostatic or sterile water (added by the end researcher) Purity: 99% by HPLC Identity: MS-verified (per COA) Storage: Protect from light Identity Basics Compound: FOXO4-DRI Synonyms: FOXO4 D-retro-inverso peptide
AOD-9604 Jump to: Structure | Mechanism | Studies | Pharmacokinetics | Protocols | Limitations | Lead Researcher | References AOD-9604 Peptide Molecular Structure & Chemical Properties AOD-9604 represents a pioneering approach to peptide-based metabolic research, originally developed in the 1990s at Monash University in Australia as a potential anti-obesity therapeutic
Instead, look for these trust pillars: Transparency: Does the company share where they source their ingredients
Microdosing means using well-below-standard starting doses of a GLP1 agonist to gain metabolic and neurologic benefits while minimizing side effects
Since then, increased whole gut permeability to larger molecular weight PEG molecules (MW 1,500 and 4,000) (146) and increased urinary excretion of sucrose in a 512 h collection (147) was reported in chronic alcoholic liver disease patients
